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AbstrACt
Purpose The Brain and Mind Centre (BMC) Optymise 
cohort assesses multiple clinical and functional domains 
longitudinally in young people presenting for mental health 
care and treatment. Longitudinal tracking of this cohort will 
allow investigation of the relationships between multiple 
outcome domains across the course of care. Subsets of 
Optymise have completed detailed neuropsychological 
and neurobiological assessments, permitting investigation 
of associations between these measures and longitudinal 
course.
Participants Young people (aged 12–30) presenting 
to clinics coordinated by the BMC were recruited to a 
research register (n=6743) progressively between June 
2008 and July 2018. To date, 2767 individuals have been 
included in Optymise based on the availability of at least 
one detailed clinical assessment.
Measures Trained researchers use a clinical research 
proforma to extract key data from clinical files to detail 
social and occupational functioning, clinical presentation, 
self- harm and suicidal thoughts and behaviours, alcohol 
and other substance use, physical health comorbidities, 
personal and family history of mental illness, and 
treatment utilisation at the following time points: baseline, 
3, 6, 12, 24, 36, 48, and 60 months, and time last seen.
Findings to date There is moderate to substantial 
agreement between raters for data collected via the 
proforma. While wide variations in individual illness course 
are clear, social and occupational outcomes suggest that 
the majority of cohort members show no improvement 
in functioning over time. Differential rates of longitudinal 
transition are reported between early and late stages 
of illness, with a number of baseline factors associated 
with these transitions. Furthermore, there are longitudinal 
associations between prior suicide attempts and inferior 
clinical and functional outcomes.
Future plans Future reports will detail the longitudinal 
course of each outcome domain and examine 
multidirectional relationships between these domains 
both cross- sectionally and longitudinally, and explore in 
subsets the associations between detailed neurobiological 
measures and clinical, social and functional outcomes.
IntroduCtIon
The significant excess of premature death 
and disability attributable to mental disor-
ders is a function of early age of onset, prev-
alence, chronicity, comorbidity with physical 
illness and alcohol and substance misuse, and 
degree of resultant impairment.1–3 Notably, 
in those aged 10–24 years, neuropsychiatric 
disorders contribute more than any other 
cause to the global burden of disease.2 4 To 
reduce this burden, earlier identification 
and enhanced long- term care of those in 
the early phases of these disorders are key 
strengths and limitations of this study
 ► This cohort tracks longitudinally a large number of 
young people presenting for mental health care and 
treatment early in the course of common mental 
disorders. It will provide detailed information about 
variations in the course of emerging illness over a 
prolonged, and developmentally sensitive, follow- up 
period.
 ► Multiple clinical and functional outcome domains 
will provide a rich dataset including assessment 
of social, educational and economic participation, 
physical health, alcohol and substance use, and 
deliberate self- harm and suicidal thoughts and 
behaviours.
 ► Linkage of longitudinal clinical data with more in- 
depth assessments from related neuropsychological 
and neurobiological substudies will increase the po-
tential for greater understanding of the pathophysi-
ological correlates of illness course in young people.
 ► As data are obtained through extraction of infor-
mation from clinical files, there is likely to be some 
under- reporting of items or missing data (both ran-
dom and non- random). Availability of follow- up data 
is biassed towards those who remain in contact with 
mental health services.
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Figure 1 The multidimensional outcomes framework and examples of the potential relationships that operate across the 
various domains over time.
priorities.3 5–9 Although 75% of mental disorders begin 
before the age of 25 years,10 current diagnostic thresholds 
and categories often map poorly onto the earlier phases 
of mental illness experienced by adolescents and young 
adults.11 12 Further, genetic, environmental, and neurobi-
ological risk factor studies call into question the validity 
of specific diagnostic entities.13–18 Consequently, services 
have been developed in Australia to promote and support 
early intervention for young people with a broad range 
of mental and substance use disorders. This includes the 
expansion of headspace centres, from a network of 10–110 
centres nationally from 2007 to 2018.19 These services 
aim to reduce adverse long- term clinical, functional, and 
other health outcomes.7 20 21
This paper reports on the methods, baseline character-
istics, preliminary follow- up rates, and initial findings of 
the Brain and Mind Centre (BMC) Optymise (optimising 
early interventions for young people with emerging mood 
disorders) cohort. Optymise is an observational study 
tracking demographic, clinical, functional, and comorbid 
outcomes longitudinally in young people who present to 
enhanced primary care–based mental health services. 
These BMC clinics are not diagnostically specific, do not 
impose a symptoms, severity, or risk- related threshold 
for receiving care, and incorporate concurrent clinical, 
neurobiological and interventional research. Research 
within these services has the specific intent of studying 
the clinical, functional, and neurobiological correlates 
of the early phases of emerging mental disorders.7 20 21 
Typically, young people attending these services present 
with a broad range of anxiety, depressive, manic- like, 
psychotic- like, or comorbid syndromes.
For in- depth examination of this transdiagnostic 
cohort, we have proposed that it is essential to use a 
multidimensional clinical and functional assessment and 
outcomes framework.22–24 This framework overtly recog-
nises that mental disorders are part of a broader general 
health construct, and are embedded within a social and 
neurodevelopmental context. Consequently, we propose 
five key clinical and functional dimensions: (1) social and 
occupational functioning (including social, educational 
and economic participation); (2) clinical presentation 
(including illness type, stage and trajectory); (3) self- harm 
and suicidal thoughts and behaviours (also incorporating 
concepts of accident and injury); (4) alcohol and other 
substance use; and (5) physical health comorbidities. 
Figure 1 shows the key domains of the multidimensional 
outcomes framework across time points and presents 
examples of potential cross- sectional and longitudinal 
relationships with particular emphasis on demonstrating 
the relationships between domains and not simply within 
the same domain over time. Social and occupational 
functioning is the primary outcome within this frame-
work, due to the significance and persistence of impaired 
functioning in mentally ill populations (even during 
periods of syndromal remission) and its contribution to 
the burden of disease.25–28 Clinical treatments and social 
and occupational interventions between time periods of 
assessment are recorded and are then considered in anal-
yses as potential mediating or moderating variables.
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The Optymise cohort has been established to provide 
longitudinal multidimensional outcomes data from a 
large, transdiagnostic sample of young people, who are 
typically presenting in the early stages of common mental 
illness syndromes. Recruitment is based on presentation 
for care and treatment rather than specific diagnostic 
criteria or severity thresholds, thus the findings are likely 
to translate well to other broadly based youth mental 
health and primary care settings. This focus on setting 
rather than diagnosis, severity, or risk- based recruitment 
is consistent with National Institute of Mental Health 
recommendations to conduct more inclusive clinical 
research in cohorts drawn from the same or similar 
settings.29–32 These inclusive cohorts are then more 
appropriate for the study of clinical or neurobiological 
constructs or dimensions of interest, and are also more 
likely to inform the development of more meaningful 
classification systems for common mental disorders.
Within the Optymise cohort, selected subgroups have 
been invited to take part in substudies with more in- depth 
measures of neuropsychological performance, structural 
and functional brain imaging, physical health (including 
anthropometric metabolic and immune function), and 
sleep–wake and circadian rhythms. These measures have 
been collected in large subsets of this population in various 
observational, longitudinal, and interventional studies 
conducted at the BMC. The Optymise cohort has been 
set up to maximise the use of data in these substudies by 
collecting broad information on individuals presenting to 
care, and linking individual clinical data between these 
associated studies and the cohort. This will enable more 
detailed investigation of the underlying neurobiology of 
mental illness in young people, as well as examination of 
the predictive value of such neurobiological measures in 
determining a range of long- term outcomes.
Cohort desCrIPtIon
Participants
Study participants are drawn from a larger cohort of 
n=6743 individuals aged between 12 and 30 years who 
presented to the BMC’s youth mental health clinics in the 
Sydney suburbs of Camperdown and Campbelltown and 
were recruited to a research register between June 2008 
and July 2018. These clinics include primary care services 
branded as headspace,7 20 21 as well as more specialised 
psychiatric services. The clinics primarily attract young 
people with a range of mental health problems (commonly 
anxious, mood, or psychotic syndromes) including those 
with subthreshold and full- threshold mental disorders. 
Young people may have been self- referred, referred 
via a family member or friend, or else via the commu-
nity including external general practitioner, school, or 
university.7 All participants received clinician- based case 
management and relevant psychological, social, and/or 
medical interventions as part of standard care. This may 
have also included referral to more specialised mental 
health services, or hospitalisation, for those whose need 
exceeded the capacity of the primary care services.
All participants (and/or their guardians) gave written 
informed consent for the use of routinely collected clin-
ical data for research purposes. No personally identifying 
information is recorded in the proforma in order to 
protect the privacy of the participants.
Patient and public involvement
Our headspace centres have an active patient advisory 
panel who are consulted regarding the development 
and application of research projects within our service. 
Findings from research studies are fed back to our young 
persons advisory group and to the users of our services. 
Results are also shared with regional and national health 
agencies, to assist with ongoing development of novel 
youth mental health services.
data collection
Research staff were trained through individual and 
group training sessions to extract key data from clin-
ical and research files and code inputs according to a 
specifically designed clinical research proforma (see 
‘Clinical proforma’ below). Clinical files included all 
available notes and records from standard clinical care, 
and research files included various assessments as part 
of participation in substudies (which may include struc-
tured or unstructured clinical interviews and the use of 
symptom rating scales). The proforma records demo-
graphic, clinical, and functional information at predeter-
mined time points. The first available clinical assessment 
at the service is taken as the baseline time point (T1) for 
each participant and the date of this assessment is used 
to determine each of the follow- up time points: T2 (3 
months), T3 (6 months), T4 (12 months), T5 (2 years), 
T6 (3 years), T7 (4 years), and T8 (5 years). If there is 
no clinical information available for any time point (ie, 
the participant did not attend the service during that 
time), then that entry is left missing. A ‘time last seen’ 
(TLS) entry is also used to capture clinical information 
from the most recent presentation to the clinical service, 
which does not always align with one of the prespecified 
time points. All clinical and research notes from the 
preceding time points, up to and including the current 
time point are used to inform and complete the current 
proforma entry. The clinical research team responsible 
for collecting the data consult regularly to resolve ambi-
guities regarding any of the proforma items and ensure 
these are dealt with consistently.
As of December 2018, phase 1 of data entry has been 
completed, with 2767 participants included in the cohort 
and 78 excluded due to insufficient data. These partic-
ipants were prioritised due to the richness of clinical 
and research data available, as a consequence of their 
participation in more detailed clinical or neurobiolog-
ical substudies. Available data from the remaining 3898 
will be entered progressively in phase 2 (commencing 
in 2019). New systematic data collection to determine 
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long- term outcomes from all original participants, using 
novel digital technologies, is planned for 2020.
Clinical proforma
The clinical proforma captures key clinical information 
regarding the following:
Demographics
Biological sex is specified at baseline (T1), and age is 
calculated at each time point.
Current engagement in part- time or full- time education 
or employment is recorded to determine Not in Educa-
tion, Employment, or Training (NEET) status. NEET is 
assigned if there was no full- time or part- time education, 
employment, training or volunteer work. Current receipt 
of any government benefits is also recorded.
Social and occupational functioning
The Social and Occupational Functioning Assessment 
Scale (SOFAS)33 is assessed at each time point. The 
SOFAS is a clinician- rated measure that assesses func-
tioning on a 0–100 scale, with lower scores suggesting 
more severe impairment. The instructions emphasise that 
the rater should aim to avoid confounding the rating with 
clinical symptoms (which has been noted as an issue with 
the Global Assessment of Functioning33–35). A SOFAS 
score of below 70 is considered to be clinically significant 
impairment.36
Clinical presentation
Mental disorder diagnoses
Mental disorder diagnoses at each time point are classi-
fied according to The Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) criteria37 and specified as 
either full- threshold or subthreshold. Diagnoses are also 
labelled as either primary, secondary, or tertiary based 
on judgement of which was the dominant presenting 
problem at that time point.
Clinical stage
Information about the course of illness is also used to 
assign a clinical stage at each time point according to a 
previously established model.6 38 39 This model provides 
a framework to assess the clinical stage of mental illness 
based on current and previous severity and frequency of 
symptoms; characteristic mental features; age of onset 
and clinical course of illness prior to presentation; 
current level of risks of harm due to illness; previous 
treatment and hospital admissions; suicide attempts or 
other risk behaviours; and current levels of social, educa-
tional and economic participation.6 These stages are an 
adjunct to formal diagnosis and the demarcation between 
stages does not equate to the cut- offs for threshold diag-
noses according to DSM-5 or other classification systems. 
Descriptions of the criteria for key stages (1a, 1b, and 
2+) within this model are outlined in online supplemen-
tary appendix A and are detailed elsewhere.6 A decision 
tree outlining the clinical staging process is provided in 
figure 2. While stages 3 and 4 are also specified elsewhere 
for recurrent, persistent and chronic illness courses, stage 
2 is our proposed cut- point for more persistent disorders 
requiring more specific and intensive clinical care and 
treatment.6 38 39 Consistent with other models of clinical 
staging used elsewhere in medicine (eg, in oncology), 
while an individual may experience clinical remission 
across longitudinal assessment, they cannot go back 
across stages when assessed at follow- up points.
Pathophysiological mechanisms
Participants with any type of mood syndrome are also 
allocated to one of three proposed pathophysiolog-
ical mechanisms on the basis of the description of the 
clinical presentation. Any cases with significant manic- 
like symptoms (manic, hypomanic, or brief hypomanic 
phenomena) or significant atypical features (eg, reduced 
activation and energy, prolonged sleep, prolonged fatigue) 
are allocated to the ‘circadian- bipolar spectrum’ subtype. 
Cases with a primary psychotic disorder or significant 
and persistent developmental difficulties (such as autism 
spectrum disorder (ASD), specific learning disability, 
or low IQ) are allocated to the ‘neurodevelopmental- 
psychosis’ subtype. Remaining cases–typically those 
reporting childhood anxiety and later stress–sensitivity 
with evolving depressive disorder symptoms are allocated 
to the ‘hyperarousal- anxious depression’ subtype. Alloca-
tion to these pathophysiological mechanisms is intended 
as an adjunct to the clinical staging model and has been 
described in detail previously.40–42 The clinical presenta-
tion is reviewed at each time point to assess the emergence 
of mania- fatigue or developmental- psychosis syndromes. 
As the entire clinical history is used to inform allocation to 
these categories, individuals assigned a circadian- bipolar 
spectrum or neurodevelopmental- psychosis phenotype 
cannot be assigned to the anxiety- depression phenotype 
at a later time point.
At-risk mental states
Clusters of symptoms that have been previously indicated 
as risk factors for progression to more severe mental 
disorders43–48 are recorded in all individuals regardless of 
diagnosis. This includes psychotic- like experiences (the 
presence of any psychotic symptoms including percep-
tual abnormalities, bizarre ideas, disorganised speech, 
psychotic- like unusual language or thought content, or 
psychotic- like disruptive or aggressive behaviour), manic- 
like experiences (the presence of any manic/hypomanic 
symptoms including abnormally elevated mood or irrita-
bility; increased motor activity, speech, or sexual interest; 
manic- like disruptive or aggressive behaviour; manic- like 
unusual language or thought content; increased goal 
directed behaviour; or decreased need for sleep), and 
circadian disturbance (the presence of significant disrup-
tion in sleep–wake or circadian cycles including the pres-
ence of a severe sleep–wake disorder or chronic fatigue). 
The distinction between psychotic- like and manic- like 
symptoms is judged within the context of the clinical 
notes.
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Figure 2 The stepwise process taken to assign those presenting for mental health care and treatment to the appropriate 
clinical stage.
Self-harm and suicidal thoughts and behaviours
The presence of suicidal ideation, suicide planning, 
suicide attempts, and deliberate self- harm since the 
previous available time point is recorded. A suicide 
attempt is recorded when a young person has actually 
taken steps to take their own life. If an individual harms 
themselves via cutting, hitting themselves, burning them-
selves, or scratching with the intention to self- harm only 
and not to take their life, then this is included as self- 
harm and not a suicide attempt. If a suicide attempt 
occurs it is also recorded whether the attempt resulted in 
hospitalisation or presentation to a hospital emergency 
department.
Alcohol and substance use
The presence of any reported use of tobacco, alcohol, 
cannabis, stimulants, or other drugs since the previous 
available time point is recorded.
Physical health comorbidities
Any major physical illness is recorded and assigned to a 
category based on type of illness.
Personal mental illness history
Known childhood- onset disorders (ie, with clear onset 
prior to 12 years old) are recorded in addition to current 
diagnoses.
Family history of mental illness
Known family history of mental illness in first- degree rela-
tives is recorded.
Treatment utilisation
Exposure to classes of medication (antidepressant, anti-
psychotic, mood stabiliser, or stimulant medication) since 
the previous available time point, and hospitalisation 
overnight or longer due to a mental health problem since 
the previous available time point (including specification 
of hospitalisation due to illness severity or suicidality) are 
recorded.
Inter-rater reliability
An inter- rater reliability (IRR) analysis was performed 
using T1 proforma recordings for 66 participants that 
were completed independently by three raters. Fleiss’ 
kappa was computed for nominal variables, and intraclass 
correlation coefficient (ICC) was computed for ordinal 
and continuous variables (see online supplementary 
appendix B).49
IRR estimates generally indicated moderate 
(kappa>0.4) to substantial (kappa>0.6) agreement, with 
excellent agreement (kappa>0.8) for some variables, 
typically those with clear defining features that would be 
expected to be well documented in clinical notes, such 
as psychotic illness, obsessive compulsive disorder, ASD 
and use of antidepressant or antipsychotic medication. 
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Figure 3 Distribution of Social and Occupational 
Functioning Assessment Scale (SOFAS) scores in the 
Optymise cohort at baseline.
Table 1 Presenting syndromes in the Optymise cohort at baseline
Primary presenting syndrome Any presenting syndrome
N Percentage of sample N Percentage of sample
Depressive disorder 1203 43.5% 1821 65.8%
Anxiety disorder 576 20.8% 1633 59.0%
Bipolar or related disorder 232 8.4% 288 10.4%
Schizophrenia spectrum or other psychotic disorder 183 6.6% 245 8.9%
Neurodevelopmental disorder 158 5.7% 388 14.0%
Disruptive, impulse- control or conduct disorder 81 2.9% 195 7.1%
Trauma- related or stressor- related disorder 109 3.9% 223 8.1%
Substance- related or addictive disorder 58 2.1% 272 9.8%
Obsessive- compulsive or related disorder 40 1.5% 139 5.0%
Eating disorder 27 1.0% 135 4.9%
Personality disorder 24 0.9% 93 3.4%
Other disorder 57 2.1% 114 4.1%
No psychiatric syndrome 19 0.7%
Any presenting syndrome includes any full- threshold or subthreshold primary, secondary, or tertiary diagnoses. ‘Other disorder’ includes 
gender dysphoria, dissociative disorders, sleep–wake disorders, and somatic disorders.
Lower reliability estimates (in the fair range: kappa 
0.2–0.4) were found for some variables, including receipt 
of government benefits, the presence of a trauma- related 
or personality disorder syndrome, suicide attempts, the 
presence of circadian disturbance, and the receipt of 
psychological therapy. Reliability estimates for childhood 
anxiety or other neurodevelopmental disorders (ie, other 
than ASD or attention deficit hyperactivity disorder) were 
in the poor range (kappa≤0.2). This indicates some vari-
ation in the scoring of these items between raters. The 
prevalence of some variables was too low to warrant calcu-
lation of IRR indices; caution should be exercised in the 
interpretation of analyses involving these variables.
baseline characteristics
Of the 6743 individuals in the research register (mean 
age at presentation to clinical services±SD: 18.4±3.8 years, 
57.3% female), 2767 participants have been included in 
phase 1 of data entry for the current study (mean age at 
study baseline±SD: 18.8±3.8 years, 58.2% female) based 
on the availability of at least one time point of clinical 
data, 78 have been excluded due to insufficient data, and 
3898 are yet to be entered in phase 2 of data entry for this 
cohort.
Occupational status indicated that 17.4% (n=481) 
were NEET; 63.7% (n=1763) were engaged in full- 
time education, employment and/or training; 14.3% 
(n=397) were engaged in part- time education, employ-
ment and/or training; and for 4.6% (n=126) it was 
unclear whether there was any current occupational 
engagement. Ratings on the SOFAS ranged from 30 to 
90, with a mean of 62.1±9.4. The distribution of base-
line SOFAS scores is shown in figure 3; 68.6% (n=1876) 
had a SOFAS score less than 70, indicating clinically 
significant impairment.
Presenting syndromes at baseline are reported in table 1, 
with more detailed full- threshold and subthreshold diag-
noses reported in online supplementary appendix C. 
Clinical stage, proposed pathophysiological mechanisms, 
and at- risk mental states are reported in table 2; the prev-
alence of self- harm and suicidal thoughts and behaviour, 
alcohol and substance use, and physical health comorbid-
ities are reported in table 3; and the prevalence of clinical 
course characteristics are reported in table 4.
Preliminary follow-up rates
Of the 2767 included participants, 2336 had at least one 
follow- up time point (that was in the range of T2 or later, 
that is, at least 1 month after baseline). The median dura-
tion of follow- up from baseline to time last seen was 14.4 
months (range 1–127 months; mean 22.9±23.2). The 
number of participants with available data and demo-
graphic characteristics for those with data at each time 
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Table 2 Clinical stage, developmental trajectories, and at- 
risk mental states in the Optymise cohort at baseline
N Percentage 
of sample
Clinical stage
  Stage 1a 804 29.1%
  Stage 1b 1625 58.7%
  Stage 2+ 338 12.2%
Proposed pathophysiological 
mechanism
  Hyperarousal- anxious depression 2024 73.2%
  Neurodevelopmental- psychosis 346 12.5%
  Circadian- bipolar spectrum 303 11.0%
  No mood syndrome 94 3.4%
At- risk mental states
  Psychosis- like experiences 599 21.7%
  Mania- like experiences 460 16.6%
  Circadian disturbance 410 14.8%
Table 3 Prevalence of self- harm and suicidal thoughts and 
behaviour, alcohol and substance use, and physical health 
comorbidities in the Optymise cohort at baseline
N
Percentage 
of sample
Self- harm and suicidal thoughts and 
behaviour
  Deliberate self- harm 1013 36.6%
  Suicidal Ideation 1240 44.8%
  Suicide planning 489 17.7%
  Suicide attempt(s) 379 13.7%
  Hospitalisation for suicide attempt 219 7.9%
Alcohol and substance use
  Any alcohol or substance use 1853 67.0%
  Alcohol use 1724 62.3%
  Cannabis use 1083 39.1%
  Tobacco use 1048 37.8%
  Stimulant use 570 20.6%
  Other drug use 432 15.6%
Physical health comorbidities
  Any major physical illness 447 16.2%
  Respiratory illness 129 4.7%
  Neurological illness 87 3.1%
  Endocrine illness 77 2.8%
  Metabolic illness 49 1.8%
  Infective illness 28 1.0%
  Immune illness 26 0.9%
  Gastrointestinal illness 24 0.9%
  Musculoskeletal illness 20 0.7%
  Gynaecological illness 19 0.7%
  Pain- related illness 19 0.7%
  Cardiovascular illness 12 0.4%
  Skin- related illness 13 0.5%
  Blood- related illness 10 0.4%
  Allergic illness 9 0.3%
  Cancer or tumour- related illness 7 0.3%
  Renal or urinary illness 4 0.1%
  Hearing- related illness 3 0.1%
  Ophthalmic illness 2 0.1%
point are shown in table 5. Follow- up data will be reported 
in more detail in subsequent publications.
FIndIngs to dAte
The BMC Optymise cohort includes individuals between 
12 and 30 years old, and the mean age at baseline was 
approximately 19 years old, consistent with the target 
demographic of the early intervention youth services. 
The gender distribution of this cohort was similar to 
that reported generally in young Australians with mental 
disorders,50 with around 58% female, but there was a 
slightly smaller proportion of females than estimated 
in the national population of individuals presenting to 
headspace centres.51 The sample with available data at 
each of the longitudinal follow- up time points were fairly 
similar to the baseline sample in terms of age; however, 
the percentage of female participants increased at longer 
follow- up intervals, suggesting that females in this popu-
lation may engage with care for longer periods of time.
Baseline social and occupational functioning as 
measured by SOFAS ranged from good functioning 
to a complete inability to function, with the average in 
the range of moderate impairment and close to 70% of 
the sample in the range of clinically significant impair-
ment, demonstrating the widespread nature of functional 
impairment early in the course of mental illness.52–54 
Further, approximately 17% were already not engaged 
in education, employment or training at baseline, similar 
to the rate reported in headspace clients nationally55 and 
higher than general population estimates in this age 
group (11.4% of Australians aged 15–29 years old).56 Our 
initial report on changes in social and occupational func-
tioning across the course of care in this cohort57 indicates 
that only around a quarter of participants experience 
reliable improvement, with functioning either deterio-
rating or remaining the same in the majority. This chronic 
functional impairment should be a high priority target 
for intervention efforts, given the significant contribu-
tion of poor functioning to the burden of disease,25 27 and 
associations between poor functioning and other adverse 
outcomes.58–60
Baseline diagnostic information indicates that the most 
common primary presenting problem was a depressive 
syndrome, followed by anxiety, bipolar, and psychotic 
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Table 4 Clinical course characteristics in the Optymise 
cohort at baseline
N
Percentage 
of sample
Personal mental illness history
  Any childhood disorder 364 13.2%
  Childhood ADHD 151 5.5%
  Childhood ASD 77 2.8%
  Childhood anxiety disorder 66 2.4%
  Other childhood 
neurodevelopmental disorder
56 2.0%
  Childhood depression 41 1.5%
  Childhood behavioural or 
conduct disorder
24 0.9%
  Childhood OCD 12 0.4%
  Other childhood disorder 11 0.4%
Family history in first- degree 
relatives
  Any family history of mental 
illness
1270 45.9%
  Family history of depressive 
disorder
835 30.2%
  Family history of anxiety disorder 404 14.6%
  Family history of alcohol use 
disorder
249 9.0%
  Family history of bipolar disorder 216 7.8%
  Family history of substance use 
disorder
184 6.7%
  Family history of psychotic 
disorder
126 4.6%
  Family history of suicide 44 1.6%
Treatment Utilisation
  Psychological therapy 1501 54.3%
  Any psychiatric medication 1373 49.6%
  Antidepressants 1068 38.6%
  Antipsychotics 475 17.2%
  Stimulants 244 8.8%
  Mood stabilisers 209 7.6%
  Any hospitalisation 635 23.0%
  Hospitalisation due to severity 281 10.2%
  Hospitalisation due to suicidality 218 7.9%
ADHD, attention deficit hyperactivity disorder; ASD, 
autism spectrum disorder; OCD, obsessive compulsive 
disorder.
syndromes. This is consistent with reports that, although 
anxiety disorders are the most prevalent mental illnesses 
in young people,50 61 mood disorders are generally asso-
ciated with greater help- seeking and service use.62 63 The 
prevalence rates of full- threshold diagnoses were slightly 
higher in our sample than those reported in headspace 
clients nationally.51 For almost all diagnostic categories, 
the prevalence of subthreshold or unspecified cases was 
greater than the prevalence of full- threshold disorders 
(see online supplementary appendix C), highlighting 
that, despite being help- seeking, the majority of our 
sample experience syndromes that do not meet formal 
diagnostic criteria at presentation to care. This illustrates 
the inadequacy of traditional diagnostic classification 
systems for describing the experiences of young people at 
early stages of mental disorders, in whom levels of distress 
and disability are high, clearly warranting intervention 
even in the absence of such formal diagnoses.7 51 64–66
Further, the prevalence of at- risk mental states was more 
substantial than both full- threshold and subthreshold 
bipolar and psychotic diagnoses, suggesting that such 
features are common in those presenting to youth mental 
health services, occurring much more frequently than 
overt psychotic or bipolar disorders. The prevalence of 
psychosis- like experiences in this sample is higher than 
the 6%–12% reported in adults and adolescents in the 
general population67–69 but lower than previous reports 
in young people presenting for mental healthcare, 
which have found prevalence closer to 50% even in non- 
psychotic samples.70 71 The more conservative prevalence 
in the current study is likely due to the method of data 
collection, as less severe psychosis- like symptoms may not 
have been specifically assessed or recorded by clinicians.
The distribution across clinical stages of young people 
presenting to our early intervention services has varied 
somewhat across previous reports7 64 66 72; however, 
the broadly consistent pattern of the majority of cases 
presenting at earlier stages (1a or 1b) is reproduced in 
the present sample. The present study provides the largest 
sample to date with clinical stage data using this model, 
and assessment at the earliest available clinical time point 
provides an estimate of the distribution across stages as 
close to first presentation to care as possible. Our report 
on longitudinal transition rates from earlier to later clin-
ical stages in the Optymise cohort indicates a low risk of 
progression to later stages in those presenting at stage 
1a, and a more substantial risk of progression in those 
presenting at stage 1b.73 A number of baseline factors 
are associated with these transitions including manic- like 
and psychotic- like experiences and lower social and occu-
pational functioning for stage 1a to 1b transitions, and 
psychotic- like experiences and circadian disturbance for 
stage 1b to 2+ transitions.73
The proportion of individuals assigned to the three 
proposed pathophysiological mechanisms (hyperarousal- 
anxious depression, circadian- bipolar spectrum, and 
neurodevelopmental- psychosis) differed somewhat from 
previous reports,40 74 with a greater proportion of the 
current sample in the hyperarousal- anxious depression 
subtype. This is likely due to the fact that the current 
report describes the profile of individuals at the first 
available clinical time point, whereas previous reports 
have used all available information, and have not been 
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Table 5 Key baseline characteristics of included participants at each time point
Baseline 3 months 6 months 12 months 24 months 36 months 48 months 60 months
N 2767 1690 1257 1074 691 466 288 199
Sex (% female) 58.2 59.6 61.7 61.6 59.2 63.1 63.5 63.3
Baseline age (mean±SD) 18.8±3.8 18.4±3.6 18.4±3.6 18.4±3.6 18.7±3.8 18.6±3.8 18.5±3.7 18.4±3.7
Baseline SOFAS (mean±SD) 62.1±9.4 62.3±9.1 62.3±9.0 61.7±9.4 61.4±9.1 61.1±8.8 60.9±9.0 61.0±8.6
SOFAS, Social and Occupational Functioning Assessment Scale.
restricted to this early point in clinical care. The emer-
gence of circadian, manic, or psychotic phenomena 
may occur at various points across the course of illness; 
therefore, a greater proportion of individuals in the 
circadian- bipolar spectrum and neurodevelopmental- 
psychosis subgroups would be expected at later time 
points. Accordingly, initial longitudinal data indicate 
that around 13% of those in the Optymise cohort transi-
tion across these pathophysiological mechanism pathways 
during the course of care, with an additional 14% transi-
tioning to later clinical stages within the same pathway.42 
Clinical staging and pathophysiological mechanisms are 
independent but complementary classification systems, 
with clinical stage reflecting the severity and persistence 
of illness, and proposed pathophysiological mechanisms 
reflecting the type of illness.
Deliberate self- harm and suicidal thoughts and 
behaviour were common at baseline, with rates concor-
dant with previous studies in mentally ill samples75 76 and 
much higher than the general adolescent population.77 78 
The presence of such high rates of deliberate self- harm 
and suicidal thoughts and behaviour early in the course 
of care highlights the specific need for risk reduction 
strategies and ongoing management of these thoughts 
and behaviours during care and treatment. A report on 
suicide attempts in this cohort79 found that the presence 
of a prior suicide attempt at baseline increases not only 
the risk for subsequent deliberate self- harm and suicidal 
thoughts and behaviours but also other negative outcomes 
including onset of alcohol or substance use disorder and 
bipolar disorder. This demonstrates the utility of this 
dataset in assessing prospective risk for multiple outcome 
domains in relation to baseline features.
strengths And lIMItAtIons
The Optymise cohort will provide an important resource to 
evaluate outcomes and understand the course of mental 
illness in young people presenting for mental health 
care and treatment. The large transdiagnostic sample, 
and selection based on presentation for care rather than 
specific diagnostic, severity, or risk- related criteria, allows 
for appropriate variance along dimensions of interest 
and provides a sample representative of those presenting 
to clinical services. This approach maximises the poten-
tial for clinically meaningful conclusions to be drawn. 
The assessment of multidimensional outcomes affords 
an important level of detail. It will allow examination of 
inter- relationships between these domains and inform 
appropriate confounding factors to be considered in 
subsequent analyses. Longitudinal assessment, using all 
available data will be another strength of this study, with 
standardised follow- up time points as well as a ‘time last 
seen’ time point capturing information across the full 
duration of time in care. The linkage of this longitudinal 
data with more in- depth assessments from related neuro-
psychological and neurobiological studies will further 
strengthen the richness of this dataset and increase the 
potential for greater understanding of the underpinnings 
of the development of mental illness in young people.
There are important limitations of this study. Due to 
the method of data collection (ie, data extraction from 
clinical and research files), there is considerable vari-
ability in the quantity and quality of clinical information 
available. This has an adverse impact on the consistency 
of the measures. It is important to note that this will likely 
result in some under- reporting or conservative estimates 
of the incidence of certain parameters, as the absence of 
clinical information may mean the information is unavail-
able or missing, not assessed by the clinician, or simply 
not clinically relevant. However, the data most consis-
tently available in clinical files likely reflect the measures 
that are most widely used by treatment providers in an 
everyday context. This will increase the generalisability of 
the findings and take advantage of existing approaches to 
clinical assessment. It is also important to note that those 
with available follow- up time points are drawn from those 
continuing to engage with clinical care over a longer 
period. This may introduce some bias in the follow- up 
sample towards those individuals with more severe, 
persistent, or recurrent illness.
ConClusIon
This paper reports on the methods, baseline character-
istics, follow- up rates, and initial findings of the BMC 
Optymise cohort, an observational study tracking a range 
of demographic, clinical, functional, and comorbid risk 
outcomes longitudinally in young individuals presenting 
for mental health care and treatment. The cohort is 
broadly representative of young people presenting to 
mental health care services in terms of demographic and 
clinical features. Initial publications from the cohort indi-
cate a number of factors are associated with transition to 
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later clinical stages, long- term social and occupational 
function typically remains poor, and that prior suicide 
attempts at baseline are predictive of a range of nega-
tive outcomes. Further work in this cohort will follow 
the longitudinal course of mental illness and associated 
multidimensional outcome domains in young people 
presenting for mental health care and treatment, and 
will allow for testing of the relative predictive validity 
of various illness characteristics and outcome domains. 
Future plans include exploring the bidirectional longitu-
dinal relationships between functional recovery and other 
adverse outcomes, characterising longitudinal transitions 
across clinical stages and pathophysiological mechanisms 
to provide greater insight into the emergence and devel-
opment of specific syndromes across the course of care, 
and analysing the predictive value of at- risk mental states 
in relation to multidimensional outcomes. Characterising 
the longitudinal relationships between the clinical, func-
tional, and other associated risk factors in this population 
(including associated neurobiological factors) and inves-
tigating their predictive value across multiple outcomes 
domains is important for the development of prevention 
and intervention strategies to improve mental health care 
and address the broad range of outcomes contributing to 
the burden of disease.
CollAborAtIon
The BMC welcomes collaboration involving the Optymise 
cohort, subject to appropriate ethical approval, permis-
sions and research agreements. This may include collabo-
ration on analysis of the currently available data, as well as 
collaboration on collection of new data at follow- up time 
points and further substudies with measures in a specific 
domain. Interested parties should contact  ian. hickie@ 
sydney. edu. au with details of the proposed collaboration.
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